The University’s coronavirus testing facility has passed a significant milestone of more than two million tests processed in the first eight months of its operation. The Cambridge COVID-19 Testing Centre is the result of a collaboration between the University and two major pharmaceutical partners, AstraZeneca and GlaxoSmithKline (GSK). The testing centre was brought under the Government’s national diagnostic lab network soon after its launch during efforts to bolster the UK’s testing capacity earlier this year. The University teamed up with the two pharmaceutical partners to combine their drug discovery and technology research expertise with the University’s leading interdisciplinary research to establish the new testing centre at the rapidly-repurposed Anne McLaren Building on the Cambridge Biomedical Campus.